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ABSTRACT
A STRATEGIC ANALYSIS AND REORGANIZATIONAL 
APPROACH DUE TO THE CHANGING MARKET CONDITIONS 
FOR BIOTEK M EDKAL
MERT AYGEN 
M B A. THESIS
SUPERVISOR; FRED WOOLLEY
Biotek Medikal is operating in the service industry since 1986. It became a leading firm in 
importing and selling bio-medical instruments and disposables (single use); particularly for 
cardiovascular surgery (CVS) and cardiology. (CRD)
In 1989, due to sales expansion, need for assistance in sales activities forced the company 
to expand the existing sales force. Branch offices in Istanbul and Izmir were opened 
in that period. Until then, service to other parts o f Turkey has been handled from the 
Ankara office.
In 1990, a drop was recorded in sales. Unplanned expansion, lack o f coordination in sales, 
the general manager's concentration on administrative issues rather than sales were the 
major causes o f the drop in sales that year. The Gulf Crisis made the situation even worse 
by delays in shipments from suppliers and changing policies in payment schedules by 
reimbursement agencies. When the crisis started, the Health Budget funds were transferred 
to probable emergency cases in the Southeast. For the first time, Biotek experienced 
serious payment problems with its suppliers due to late collection o f its receivables .
The biggest devaluation in the republic's history in April 1994 led to a further crisis in the 
medical sector due to import dominant structure. Shortly after this devaluation all health 
care reimbursement entities ran into financing problems which had an impact on local 
distributors and suppliers as well. This was a fast growing market and most of the other 
competing firms were also enjoying the market conditions before the reshaping o f the 
relations o f hospitals with reimbursement agencies.
Biotek is now facing the challenge o f organizing its structure to adapt to the rapid growth 
o f the firm and the changes in the industry. In addition, Biotek has to struggle with the 
government regulations dictating the policy change in payments o f the state owned 
enterprises.
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In terms o f the basic elements o f the strategic management process, the thesis focuses only 
on environmental scanning and strategy formulation. Reference 1
In the environmental scanning, the thesis analyses the opportunities and threats that Biotek 
Medikal faces in the medikal market. Here the task environment o f Biotek Medikal is 
clarified by reference to the bargaining power o f buyers and suppliers and the competition 
among the competitors.
The environmental scanning analysis also addresses the internal environment o f Biotek 
Medikal in which the strengths and weaknesses o f the company and its competitors are 
examined through technical capacities, human resources, market relations etc. Reference 2
Based on the findings of the earlier chapters, the final chapter tries to formulate strategies 
for Biotek Medikal designed to improve the competitive position o f the company's 
products within the medical disposable market.
Here particularly the following points are questioned; Should Biotek compete on the basis 
o f low cost or should it differentiate its products on some basis other than cost such as 
focusing on the most profitable product lines or, if present, finding market niches. 
Reference 3
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In conclusion different alternative strategy formulations are evaluated in terms o f Porter's 
competitive strategy i.e., cost focus, cost leadership. Reference 4
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ÖZET
DEĞİŞEN PAZAR ŞARTLARINA GÖRE BİOTEK MEDİKAL 
İÇİN STRATEJİK ANALİZ VE RE-ORGANİZASYONEL
YAKLAŞIM
MERTAYGEN 
M.B.A Tezi
Tez Yöneticisi: Dr. Fred Woolley
Biotek Medikal 1986 yılından beri medikal sarf malzeme satışı ve servis sektöründe 
çalışmaktadır. Şirket Kardiyoloji ve Kalp-Damar cerrahisinde önemli satış hacimlerine 
ulaşmıştır. İthalatçı bir firma olan Biotek Medikal, alaranda satışta lider şirketlerden biri 
olmuştur.
Biotek'in hayatımn incelenmesi sırasında bazı önemli aşamalar mevcuttur. Bunlardan biri 
1989 yılında İstanbul ve İzmir şubelerinin açılmasıdır. Daha sonra ortaya çıkan "körfez
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krizi" ise bütün Türkiye'yi olduğu gibi medikal sektörü de önemli ölçüde olumsuz 
etkilemiştir.
Otramdaki en son değişiklik ise Nisan 1994 deki Cumhuriyet tarihinin en büyük 
devalüasyonu ile olmuştur. Bu devalüasyon, tüm sosyal güvenlik organizasyonlanmn ve 
devlet hastanelerinin, finansal problemlerine çözüm bulabilmek amacıyla yeniden 
yapılanmalarını gerektirmiştir.
Biotek şimdi hızlı gelişmiş yapışıra sektördeki değişikliklere adapte edebilme ikilemi ile 
karşı karşıyadtf. Buna ek olarak, Biotek sağhk harcamaları ve ödemeler konusundaki yeni 
hükümet kanunları ve politikaları ile de mücadele etmek zorundadır
Bu tez, Biotek'in dğişen bu pazar ortamı koşullan karşısında stratejik olarak nasıl bir 
politika izlemesi konusunda alternatifler getirerek öneriler sunmaktatır.
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CHAPTER I. INTRODUCTION
Medical device and consumables sector is one o f the emerging sectors in Turkey. It is 
observed that the high rate o f population growth in Turkey is calling for increased number 
o f hospitals, surgeries and therapies attended.
Biotek Medikal is operating in a segment where costs are high and new product turnovers 
are above the whole industry.
Medical disposable business has its advantages and disadvantages mostly raised by 
government approach to health care in terms o f financing or ignoring
This study presents an overview o f how Biotek is re-organizing its structure and strategies 
for the challenges it has been facing the last couple o f years and will face in the future.
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Biotek is operating in four major market segments; Oxygenator (Terumo), pacemaker 
(Intermedics), PTC A (Percutaneous Transluminal Coronary Angioplasty - ACS), and 
heart valves (ATS). In a typical invoice, an item from one o f these segments is 
accompanied with several accessories or complementary goods. There are other minor 
products, such as blood filters, surgical drapes and gowns, blood transfusion sets and 
grafts, which are either recently introduced to the markets or have low sales figures. Trend 
in these days is towards buying these products by sealed public tenders.
In 1994 Biotek Medikal accounted for 30%  market share in Oxygenator, 10% in 
pacemaker, 25%  in PTCA and 8%  for heart valves. Ignoring all accessories and 
complementary products sold together with the leading item o f each segment, the four 
main products alone accounted for 60%  o f all Biotek Medikal sales (17%  for 
Oxygenator, 16% for pacemaker, 20% for PTCA, and 7%  for heart valves).
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PRODUCT SUPPLffiR MARKET
SHARE
PERCENT OF 
SALES
DESCRIPTION
Oxygenator Terumo 30% 17% Artificial lung
Pacemaker Intermedies 10% 16% Device to 
support heart
PTCA catheter ACS/Guidant 25% 20% Balloon 
dilatation 
device for 
arteries
Heart valve ATS 8% 7% Artificial heart 
valve
Table 1 Products and Suppliers
Page 10 of 48
CHAPTER II. GENERAL MARKET OVERVIEW
2.1. CLIENTS AND THE MARKETING ACTIVITIES
Before an organization can begin to formulate strategy, management must scan the 
external environment to identify possible opportunities and threats. Environmental 
scanning is the monitoring, evaluating and disseminating o f information from the external 
environment to key people within the corporation. It is a management tool for avoiding 
strategic surprise and ensuring the firm's long term health. Research has identified a 
positive relationship between environmental scanning and profits. Reference 1
The major clients o f the company are doctors and surgeons in hospitals. Unfortunately, 
these clients who do not pay for the products since they have no legal obligation to the 
payer (SSK, Emekli Sandigi, private insurance companies, and non-insured patients). They 
are free to write any prescription they like.
A lot o f small firms are entering medical disposable business with the hope of establishing 
good relationships with a hospital. It is important to note that persuading the key doctors 
in a hospital may be enough to generate sufficient cash for a firm to survive and even to 
achieve an advantageous position in the market in general. Therefore, the market shares 
differ for each product and market positions are continuously under attack. Thus, every
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firm must do its best to convince the doctors in hospitals in order to sustain the 
competitive advantages possessed. This involves all kinds o f promotion activities. For 
instance, one o f the competitors even hired additional staff to serve the key doctors in 
their extra mural activities. Another frequently used promotion is the provision of medical 
journals and the arrangements for the attendance to the relevant congresses and seminars 
both domestic and international . Actually, these efforts are essential to develop the 
market.
Sales promotion and personal selling are the primary marketing activities. A direct contact 
is made with doctors in the introductory stage. Prospects are first visited by the sales 
engineers. When a solid relationship is formed with the doctor and the sales representative, 
the president or the top manager of the company is asked to join a visit. It is particularly 
important in the industry to have top management support in promotion and/or closing 
the deal.
In big hospitals like TYIH, Hacettepe, and Kosuyolu where heart surgeries have old 
histories, doctors are very experienced. They have relationships with particular 
distributors, and tight bonds were formed long ago. Switching a doctor from one 
distributor to an other requires patience, time, and continuous follow-up for a company.
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In order to "tie" doctors, they are periodically visited, products are emphasized, and 
relations are deepened. For a successful sales person, increasing social relationships with a 
doctor is also important. Joining a meal or a drink, arranging a football game, or simply a 
friendly chat may have considerable effects in the overall result.
In most hospitals the head o f the department usually gives the ultimate decision on which 
products to be purchased and used. The companies need approval or support of the key 
doctor to be confident for their success. When it is impossible to "tie" the key person of 
the department, companies go for junior doctors who will eventually replace the top man. 
This practice promises long term results, and only works out if the target doctor(s) reach a 
powerful position in the hospital.
For doctors who do not have experience with the operations, companies have to take a 
teaching and guiding role. Since the hospitals where few operations are held are small 
markets, it is easier to access the key doctors.
2.2. SIGNIFICANT CHANGES IN THE MARKET
Possibly no one in the sector could foresee the detrimental effects o f the biggest 
devaluation which took place in April 1994. Shot was around 40% overnight but together 
with ongoing daily adjustment o f foreign currencies, exchange rate has increased by 149% 
for USD / TL parity at the end o f 1994. This has put enormous burden on account
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payables for Biotek since all collectibles were in TL where as debts are in foreign 
currency. The situation was painfiil since company was caught to this crisis with a large 
sum o f receivables outstanding in local currency and almost a few inventory items.
Health care reimbursement agents like SSK and pension fund formulated “ package deals“ 
with hospitals for cardiac diseases dictating unrealistic charges to be allowed. All these 
have created enough turmoil to be faced by companies in this market segment.
Besides is a comparison o f “package deal” prices in respective global markets.
TURKEY USA
Open Heart Surgery
PTCA
Pacemaker
$4,000
$1,700
$4,000
$30,000
$18,000
$20,000
Table 2 Cost of cardiac interventions
Besides, the retiring age in Turkey is lower than European standards (men work for 25 
years, women work for 20 years to retire). The ratio o f working people to retirees is 
nearly 2:1 in Turkey compared to about 6:1 in Europe. Consequently, the payments from 
workers to SKK are not sufficient enough to cover health and salary expenditures for 
workers and retirees. Furthermore SSK is not allowed by government bodies to freely
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utilize its funds in their best interest. Governments, in the last two decades has used up all 
cash funds or rent incomes o f SSK for financing other obligations and hence caused these 
funds diminish in time and purchasing power of these savings has lost substantial value. All 
these factors above make it difficult for SSK to manage its cash effectively and profitably. 
Hence, debts cannot be paid in a timely manner, this causes trouble to companies which 
directly or indirectly interact with SSK.
With its considerable market shares, Biotek is not able to escape from encountering the 
problem o f the whole industry. Company records showed that 18% o f the total receivables 
in April 1994 were direct invoices to SSK, and a further 52% were invoices to hospitals 
(other than SSK hospitals) for patients insured by SSK.
With Biotek Medikal's effort, the firms in this industry gathered in May 1994, so that they 
would take a common action against the situation faced. They declared a consent decree 
not to supply any material to SSK without any cash or 30 days payment terms. This 
meeting would serve for the benefits o f the industry if the conditions were fully satisfied, 
but the violation o f the agreed actions by a few competitors resulted in the failure o f this 
effort. One o f our main competitors, Bi9ak9 ilar is also a manufacturing company 
producing low-tech items and employs ordinary workers (about 240) to continue 
production. Besides, their portfolio is much broader than other competitors. They claimed 
that this policy would result in big problems with their workers and production costs.
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Therefore, they started the delivery again breaking up the agreement. Medistar followed 
Bi^akiilar, and so the others did. Now, the increased distrust among the competitors 
leaves each firm alone in dealing with the problems. The disappointment and distrust are 
reflected in current strategies o f Biotek Medikal, too. The company prefers to live with 
the financial problems until when a more healthy industry structure is achieved.
These financial difficulties are expected to serve as a barrier to entry for this industry so 
that a few larger competitors will sustain their market positions in a more preferable 
industry structure. Biotek will make use o f its own strong credibility advantage and its 
relatively strong market position for the survival in these difficult days. But management 
is aware of the fact that if the situation would not be corrected in a reasonable time period, 
company may also suffer from the friction with its suppliers.
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CHAPTER ill. INDUSTRY ANALYSIS
3.1. ATTRACTIVENESS OF THE INDUSTRY
In scanning its industry a corporation must assess the importance o f the following six 
forces to its success: threat o f new entrants, rivalry among existing firms, threat o f 
substitute products, bargaining power o f buyers, bargaining power o f suppliers, and 
relative power of stake holders. Reference 6
The industry is attractive because o f the rapid growth rate in the CVS and CRD 
operations. On the basis o f Western statistics, 60,000 open-heart surgeries per year should 
be conducted in Turkey. In 1995, total CVS operations added up to a total of 14,532, and 
angioplasties (cardiology) to 4,600. The balance in the United States is changing in the 
favor o f angioplasties. In 1992, for the first time in history, total number o f angioplasty 
cases exceeded the number o f open-heart surgeries in USA.
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Below is a comparison o f number o f treatments per million inhabitants in Turkey 
and USA.
TURKEY USA
Open Heart Surgery 250 625
PTCA 114 664
Pacemaker 20 138
Table 3 Comparison o f intervention distribution
This table suggests that there is still a big gap between the potential and what we are being 
able to address currently in Turkey. It is hoped that with the development o f the country 
as a whole these figures like in USA would be attained and business would be more 
justifying for those involved.
Increasing knowledge in CVS and CRD, founding o f new private hospitals, and 
increasing health insurance services affect attractiveness o f this medical sector 
positively day-to-day. Among the specialties o f medical care, cardiology is the most 
demanded for skill and expertise since failure o f therapies may result with loss o f lives o f 
patients which may not be case for most other medical divisions. One should also keep in 
mind that besides the high risk o f the patient group and the treatments itself, Turkish law 
system does not cover for any mal-practice issue or similar. Therefore, hospital deaths
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or morbidities caused by mistreatments go unnoticed and no enforcement by legal actions 
are possible. This, o f course, makes industry attractive as well since it is relatively high 
margin speciality o f medical care compared to other disciplines.
On the other hand, there are high entry barriers to this industry:
There exist economies o f scale as the promotion costs per unit decreases by the increasing 
volume o f sales. There is no significant competitive advantage for a new entrant due to 
product diflferentiation because all o f the existing products offer similar benefits and have 
satisfactory quality. Capital requirements are not as high as manufacturing industries. 
Depending on the market, there may be a need to build inventories as in the PTCA market. 
Since personal relationships are an essential part o f the operations, a new entrant has to 
establish contacts with the doctors and surgeons, which may demand a high start-up 
promotional budget. New entrants should also be ready to challenge late payment 
character o f the market.
There are also cost disadvantages independent o f the size o f the firm. To find a supplier 
may be costly for the potential entrant because most o f the foreign suppliers require solid 
references o f worldwide known and respected companies. Also, finding a strong supplier 
may be difficult as most o f the well-known brands are already represented in Turkey.
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Furthermore, the exchange rates will affect the business negatively for payments will be in 
foreign currencies whereas the sales will be in TL.
The most critical barrier to entry is the government policy. The import tariffs are regulated 
by the government, which directly influence the material costs. Budgets o f some o f the 
hospitals are determined by the Ministry o f Health, which is related with the total 
expenditures the hospital can make in a certain fiscal year. Finally, SSK's payment 
schedule is supported by the government although this should not be the case in real life. 
Therefore, the potential entrant's cash generation is affected by the government policy.
3.2. BARGAINING POWER OF SUPPLIERS
Since a very few o f the instruments and disposables are produced in Turkey, all 
companies operating in the industry have to find a foreign supplier. Many distributor firms 
want to be representatives o f the respectable suppliers. Therefore, if the domestic 
distributor cannot perform satisfactorily, the supplier has the power to replace the firm 
with another distributor. As a result, the suppliers try to ensure their own benefits by 
setting annual purchase quotas, putting possibly minimum liabilities for themselves in 
the contract and short payment periods granted to the distributor since there are always 
numerous companies willing to do business.
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If  the supplier cancels the contract, the distributor may end up with high losses due to any 
expenses or investments already being made for the sake o f future business.
All these factors show that suppliers have strong bargaining power over the distributors.
3.3. BARGAINING POWER OF BUYERS (Hospitals and doctors)
Buyers affect industry through their abihty to force down prices, bargain for higher quality 
or more services, and play competitors against each other. A buyer, in our case the 
doctors and the hospitals is powerful if some o f the following conditions hold.
•  A buyer purchases a large proportion o f the seller's product or service.
• Alternative suppliers are plentiful because the product is standard or undifferentiated.
• Changing supplier costs very little.
• A buyer earns low profits and thus is sensitive to cost and service differences.
Since the products are almost standard and satisfy the required quality level, most buyers 
(especially older doctors) are not product conscious. The distributor should estabUsh good 
relationships with the buyers to continue business. Switching costs are low for the buyers 
because some o f the products are dependent on the instrument which is left as 
consignment to the hospital and ownership still belongs to the distributor, and some others
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do not require a brand-specific instrumentation. Consequently, the one who builds up 
good relationships with the buyers becomes the dominant distributor to the hospital; hence 
there is strong bargaining power o f buyers. I f  the package deal attempt would be 
approved, this attitude may change since then SSK would not care o f the products used in 
the treatment but would pay a flat fee to the hospitals. This may, o f course, change the 
purchasing policy o f the hospitals towards the cheapest offers.
3.4. COMPETITIVE RIVALRY
Competitors are numerous and roughly equal in size and power. Industry is still growing. 
In the light o f global statistics, the expected rate o f annual open-heart surgeries in Turkey 
should be about 60,000; however the actual rate was about 14,000 in 1995. There are two 
ways o f increasing the capacity o f hospitals; establishing private hospitals or increasing 
government expenditures on health. Ministry o f Health budget in 1995 was 1.8% o f GNP 
where as this figure averages 8% in OECD countries.
As stated above, there are low switching costs to buyers causing an intense competition 
among the firms to be the preferred distributor. The exit barriers could be high if the 
market segment requires an initial investment. In the short run, an unsuccessful entrant 
may have high losses due to the costs o f the initial promotional budgets.
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Rivals are diverse in origins, personalities, resources and strategies. For example, 
BI(^AK(j];n.AR is not a technical oriented company but has the advantage o f being the first 
in the industry. It does not have to worry about promotion and technical assistance. As 
long as the key people "tied" by Bi9ak9ilar stay in their positions, they will continue to be 
dominant in those hospitals. On the other hand, ETA is engaged in rather unethical 
financial activities, and tries to compensate for its high promotional budget by overpricing 
its materials.
Sustainable competitive advantages and the Biotek's position in the industry will outline 
the factors in determining its competitive strategy.
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CHAPTER IV. COMPETITOR ANALYSIS
4.1. GENERAL
Michael Porter proposes two "generic competitive strategies for outperforming other 
corporations in a particular industry: Lower cost and differentiation. Reference 1
In this chapter the following dilemmais discussed; Should Biotek compete on the basis o f 
low cost or should it differentiate its products on some basis other than cost such as 
focusing on the most profitable product lines or if present, finding market niches. Reference 
8
Research generally supports Porter's contention that a firm that fails to achieve a generic 
strategy is going to be stuck in the middle with no competitive advantage. Reference 5
Competitors enhance the ability to differentiate, since they do not provide extensive 
technical expertise and after sales support. Biotek provides technical assistance, and 
creates a value to the customers for what it has been marketing.
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Competitors provide a cost umbrella. I f  one o f them increases or decreases prices the 
others follow. They motivate each other. A new promotional technique or a new product 
is followed by all the competitors. They also help to increase the industry demand by 
encouraging doctors to make more surgeries and by training them and improving their 
knowledge. In this way they contribute to the market development and share the costs 
of the development.
Competition is indeed provide a second or third source to buyers. The industry is not 
purely dependent on a single supplier. They offer a standardized technology. To be able 
to survive in a health related market, the products should have a minimum acceptable 
quality level.
Until now, the good characteristics o f the competitors were described. However, 
competitors are not that good from a particular firm's perspective. First, the current 
structure o f the industry is created by most o f the existing firms. Companies promoted 
their trade names instead o f promoting what they sell in the industry. This ultimately 
started restricting their maneuvering capabilities since the structure became rigid, and 
led them to work more and more on sharpening an image. It is going to be an interesting 
phenomena to see if this strategy would prove useful for the case with “ flat treatment 
charges “ policy o f SSK (package deal).
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Likewise, firms competing in the same market failed in improving their bargaining 
positions. First, they could not overcome the payment problems originating from SSK 
and hospitals. They could come to an agreement only once which failed since some o f 
the firms preferred to go for short-term benefits even without having any solid feedback 
from the state or SSK.
4.2. MAJOR COMPETITORS OF THE COMPANY
1- BIÇAKÇILAR
In the oxygenator market, BIÇAKÇILAR is the market leader. They offer three different 
brands o f oxygenators, and have cost advantages since they run a factory manufacturing 
some o f the side products like tubing sets, surgery tables, suction devices, plastic 
components etc. There are rumors that the company will start producing oxygenators in 
its Istanbul plant soon. The cost advantages that they have in many product lines have 
always gave them a lot o f room to invest to other product lines.
It seems to be Bıçakçılar is enjoying the profits o f well implementing the cost-leadership o f 
the Porter's generic strategies
In some hospitals, Biçakçilar operates like a single supplier, and nobody thinks o f buying 
another brand. When Biotek sales engineers visit doctors in hospitals which are committed 
customers o f Bicakcilar, the response they get is "We are happy with what they provide.
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why should we switch?". However, B iiakiilar does not think that their position will 
change in the market, therefore, they are not involved in activities to expand their 
market share any further.
The company is owned by a family, which does not have technical background. It is one 
o f the oldest companies in the market (founded 30 years ago). At the times when 
communication and import activities were limited in the country, Bi9ak9ilar enjoyed the 
advantages o f being the first and only. They did not worry about marketing and 
promotion; occasionally doctors came up with catalogues o f new products and requested 
them to provide the materials for the hospital.
Bi9ak9ilar's primary weakness is its unqualified sales force, and inadequate technical 
support. The company has extensive financial resources accumulated through the years.
2-ETA
ETA is the leader in the PTC A market. When the company was founded in 1982, the 
term angioplasty was unknown in the cardiology society. The first balloon was invented in 
the United States with a four year patent. To everyone's surprise, PTC A became one of 
the most important issues in cardiology quite soon. ETA was the only distributor in the 
Turkish PTCA market and faced no competition at the introductory period. Moreover, 
ETA helped the cardiologists to improve their knowledge in PTCA operations through
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seminars, congresses, technical demonstrations, and assistance in the surgeries. Similar to 
the Bicakcilar case, there is an emotional link with the doctors and the company. Again, 
rather than the product, the company image is very strong.
We may conclude that ETA is making a very good differentiation o f Porter's generic 
strategies by its service and image.
ETA's promotional budget is relatively higher than its competitors. For instance, in the 50 
billion PTCA market they can easily afford 3 billion for a single exhibition. This extra 
spending on promotion is reflected to their invoices. State financial authorities finally 
noticed the ongoing price strategy. In the past year, ETA was under close inspection o f 
Ministry o f Finance, and thus they have had severe financial penalties due to undeclared 
incomes and unpaid corporate taxes.
3- MEDISTAR
Market leader for pacemakers is MEDISTAR.. Their product is recognized as the best 
quality pacemaker in the world. Other than pacemakers, Medistar has a broad range o f 
medical products they represent which indeed a big consolidated in USA.. The company 
is a subsidiary o f a construction firm. They have therefore strong financial and training 
support abroad originating from their principal.
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It is obvious that Medistar has already been put in the differentiation part according to 
Porter's generic strategies by its high tech product line o f pacemakers.
Cost leadership
O Bıçakçılar
Cost focus
Reference 3
Focused differentiation
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4.3. STRENGTH & WEAKNESS ANALYSIS
1. Biotek Medikal
Strengths Weaknesses
• High marketing power o f a good sales •  Relatively young in the industry
team which is compound of engineers. •  Limited financial resources
•  High technical support and knowledge • Lack o f communication between
• Supplier support business units
• High quality products
•  Innovative suppliers
•  Good relationships with doctors
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2. ETA
Strengths Weaknesses
•  Monopoly in PTCA market for several •  Financial problems (under strict
years control o f Ministry o f Finance for tax
•  First firm founded by people with purposes)
technical knowledge in biomedical
engineering
• First to encourage and train doctors in
the angioplasty field
•  Strong promotion
• Strong relations to surgeons
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3. Bicakcilar
Strengths Weaknesses
•  Oldest in CVS market •  No technical expertise
•  Manufacturing facilities (cost •  Less emphasis on marketing
advantage)
•  Diversified product line
• Some surgeons are committed to the
firm
• Strong financial resources
4. Medistar
Strengths Weaknesses
•  Sells the best pacemaker (Medronic)
•  Extensive financial support
•  Diversified product line
•  Weak in cities outside Istanbul.
•  Lack o f sales organization
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Sustainable competitive advantages are:
(1) A good, strong, and technically qualified sales force continuously supported by the 
good technical information about the improvements. Personal relations are primary 
determinants o f success in this industry, which can only be achieved by such a sales force, 
since the customers are company conscious rather than being product conscious.
(2) Supplier support. Biotek does not have extra financial resources as some companies 
in the industry have (e g. Bicakcilar). Certainly, there are times when a company is in the 
middle o f a crisis and needs some sort o f financial support. Biotek can communicate such 
situations to its suppliers and most o f the times have their support as in the case o f delayed 
payments. The support and trust o f the suppliers increases the credibility and motivation o f 
Biotek Medikal.
(3) High quality products. Even though company recognition is far ahead o f product 
recognition it is not realistic to completely ignore the effect o f a highly qualified product. 
For older doctors, emphasizing the advantages o f a certain product is harder because they 
have traditional habits and attitudes toward some companies. However, the new 
generation doctors are more enthusiastic, and only working for the company image may 
not yield the desired outcomes.
Biotek should consider its sustainable competitive advantages while formulating a 
competitive strategy.
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CHAPTER V : RECOMMENDED STRATEGY
5.1. DETERMINING A GENERIC STRATEGY FOR BIOTEK
The appropriate generic strategy for Biotek is the fit between its value chain and the 
industry analysis. The critical activities o f the value chain indicate the sustainable 
competitive advantages o f Biotek Medikal. These advantages are the good, strong, 
technically qualified sales force, supplier support and high quality products. In such an 
industry with intense competitive rivalry, communicating these three competitive 
advantages would create a high value position in the customers' minds.
This industry is related to health and human life. Therefore, the doctors would not care 
about the price o f the products, if higher priced products would serve best for the 
treatment o f their patients. In other words, if the decision maker is not paying the bills 
himself, he is more interested in the other benefits o f buying a particular product. As 
opposed to this fact, totally ignoring the cost would be a false state o f mind for a specific 
company. Because o f the limited budgets o f hospitals, decision makers are more price 
conscious during tenders since they can not charge such bills to patients and/or 
reimbursement agents. So, trying to gain a competitive advantage only on differentiation 
basis would not work and would not be sustainable at all.
Page 34 of 48
The company authorities always state that in addition to the strong relationships with the 
surgeons, knowledge and technical skills in cardiology and CVS has led to the success. 
Before entering a new segment or broadening its market, Biotek has to consider some 
critical factors. Training o f existing and some new sales force for the new industry 
segments will take a long time and will be costly to the firm. Additionally, attracting new 
surgeons will probably need extensive efforts. In fact, currently, sales staff is already 
highly engaged vrith such promotional activities. Additional responsibilities and 
investments will be a burden on Biotek and on its sales personnel.
As a result, the competitive generic strategy for Biotek should be focus differentiation 
while not totally ignoring the cost considerations.
5.2. IDENTIFYING ALTERNATIVES
Alternative 1:
Due to the increase in accounts receivable and financial problems (loss in exchange rates, 
credit purchase problems), contraction o f the company could be a solution until the 
financial difficulties are over.
Some o f the sales people could be laid off the firm, and the administration department 
could focus on some o f the most profitable and promising products. The first obvious
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advantage o f such a change will be a decrease in the employee expenses in parallel with 
the decreasing number o f employees. This suggestion will also lead to a change in the 
promotional expenditures. Biotek will be able to spend more for the most important 
doctors while decreasing the total promotion costs. The management o f a smaller Biotek 
will be easier, so the general manager will have more time to deal with the marketing 
operations o f the company to increase the doctor satisfaction. With the reduced volume of 
sales, the total amount o f debt to the foreign suppliers and the losses due to foreign 
currency exchange rate differences until the payment date will decrease substantially.
Nevertheless, this alternative will also exhibit some unfavorable aspects. The most 
important shortcoming will be the loss o f market share, which is achieved after many years 
o f extensive marketing efforts. In this industry, there are many competitors, which are 
waiting for such opportunities to increase their market shares. It will be very difficult, or 
may be impossible to regain the lost market shares later on.
Employees who are laid off may initiate some rumors against the company. As a result, the 
image o f the company may be distorted, and some suspicions may arise concerning the 
viability o f Biotek. Consequently, a smaller Biotek is likely to loose its credibility both to 
the doctors and to the suppliers.
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The industry already suffers from the unpayable debts and the pa5mient process may give 
some priority to the largest companies with the greatest amount o f receivables. In such a 
case, a smaller Biotek will have more difficulty in the collection o f its receivables.
As the trade volume o f Biotek shrinks the support o f the supplier companies will be 
lessened in time. The costs o f the imported goods will increase when they are ordered in 
smaller lots or the suppliers will prefer not to work with a company which can sell only a 
small range o f offered products with lower quotas. It will not be logical to upset the 
current suppliers who supported Biotek in the very difficult days starting with the 
foundation o f the company.
Alternative 2:
The second alternative to be considered is establishing different companies with minority 
share holding to each o f the successful sales persons and the general manager, keeping at 
least 51% o f the shares to Biotek Medikal for control and governance purposes. Biotek 
will be responsible only for importing the materials and delivering them to the new 
companies. The new companies will be specialized only in one type o f market segment, i.e. 
one o f them operating in the CRD market, other in CVS and such. To ensure the effective 
performance o f these newly established companies, the management o f the company plans 
to set goals and quotas to those firms.
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Alternative II has several advantages. The new partners will be more motivated, because 
they will commit themselves more to their own firms, and they will work harder to 
increase the profits, so the share they will get. By the way, the owner will not be busy in 
managing operational problems, but will deal with business level decisions and strategies. 
Besides, the decision making process for each firm will be easier and faster. The 
information flow, data accuracy and analysis will be handled in a more reliable manner. 
The surgeons will have direct daily contacts with the owners or partners o f the firm, 
hence will satisfy their egos.
However, this alternative also brings disadvantages. The sales people may have superior 
skills in sales, but they are inexperienced in management and it is yet unknown whether 
they will become successful managers or not. The surgeons want to establish their 
relationships with the owners, but it will take a long time to be perceived as credible and 
respectable owners by the surgeons. Therefore, it is not easy for Biotek Medikal to stop 
engaging in selling activities, until the new owners have satisfactory perceptions in the 
surgeons' minds, in order not to lose shares in the market. In addition to this, it should also 
be noted that a new firm will bring new overhead and labor expenses. The sustainable 
competitive advantage o f the current Biotek is its effective marketing and strong sales 
force. When this sales force is split into different firms, employment and training o f some
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new qualified personnel will be required. This will be time consuming and costly, and it 
should be questioned carefixlly for feasibility.
As was noted before, most o f the relationships with doctors are fixed and firmed. 
Therefore, expecting booms in the market share in the short run is not realistic. So, it will 
not make the firm better oflF to increase operational costs for slight increases in motivation 
and shares in the market. Considering the payment problems in the industry, the firms 
should try at least to maintain the costs at the existing level for their survival.
Alternative 3:
Since the main concern o f Biotek Medikal is concentrating in cardiology and CVS, 
another option is to dissolve all sales force and operate through independent sub-dealers. 
In this case, Biotek should hold only marketing managers for CV and CRD in house to 
monitor and direct the sales activities o f dealers but meanwhile not loosing the 
connection with the ultimate clients.
With this model, Biotek might enjoy the luxuries o f not concerning payments situation 
since company will deal only with predetermined credit limits with its customers (i.e. sub­
dealers) tied up by collateral securities.
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However, Biotek, in this case, has to sacrifice fi'om operational margins as a wholesaler. 
This may give the chance of a radical shrinkage o f the company in terms o f size and 
operations.
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CHAPTER VI: CONCLUSION
Best strategy for Biotek seems to be a bundle o f available alternatives in a mixture such 
that it maximizes the return for the company; However, the key point is, o f course, not to 
loose the control and the integrity while bundling the business units. While change is on 
the way, the company has to recognize that “satisfying internal demands o f the company’s 
own organization” is crucial. Implementing this approach requires determination, 
dedication and willingness to change at all level, since it has to change the way the whole 
processes o f the trade experienced in the firm so far.
Proposed action items are as follows:
Divest product group, which has relatively low operational gross margins. Those 
products, which are strategically important to keep up for complementary reasons, should 
be exempted, fi’om this decision.
Cardiology Business: This business still requires more o f a dedicated approach, day to day 
contacts, follow up in a continuous fashion should be made by Biotek in the form o f joint 
venture companies in Izmir, Istanbul and Ankara. In this scenario Biotek would still
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import and invoice the products to those new companies. Biotek would go on to carry the 
privilege o f distributorship rights as usual.
Biotek should retain controlling shares in these new organizations, but offering significant 
shares option to general managers to make them tightly bonded to the company. Share 
options should be available in the form o f a pool o f shares determined to be outstanding 
for such a purpose. People would receive either bonus as cash or shares exchange based 
on performance criteria set for unit growth, revenue and profit targets.
Biotek should also control not only the sales but also definitely marketing channels and 
actions and set the ultimate goal and visions for the business.
Cardiovascular Surgery: It is the one where market has turned out to be a complete 
commodity. Therefore approach to this segment would be different. Since there is no 
rationale and room for two separate organizations to live, Biotek should go on to continue 
its sales and marketing efforts for this segment, with its core organization.
Expenses are expected to be reduced by 42% compared to previous year. (Exhibit 1)
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Unfortunately there seems to be little certanity for Biotek managers to prepare a budget 
plan for a 3-5 years time span due to unreliable and unstable governments and policies in 
the last decade.
Investment should be made physically to better communication tools like on-line computer 
networks between Biotek and its sister companies. This would enable head office to help 
office to marketing and sales as well as for monitoring purposes.
Company should also look forward to diversify in not necessarily heavily products for 
cardiac diseases but in other medical disciplines too. The target group should be the one(s) 
where government interventions like “package deal” or “flat fee” approaches not yet 
applicable or difficult to apply.
It is shown that although proposed plan is reducing the head office or principle 
organization’s overheads by partly shifting expenses to spinned-ofF companies, there is a 
limit where company can no longer reduce expense items for healthy operations.
It is obvious that Biotek should find new avenues to increase its revenues and net profits 
without absolute downsizing or re-organizing the whole system.
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Message and vision should be clearly communicated to all employees and the commitment 
o f top management group should be secured towards the goal. Another key ingredient o f 
this plan is the knowledge and information flow between the business units. ‘Expertise 
focused organizations need to be formed with small headquarter intervention and 
headcount to successfully adopt the system” Senior managers should devote their time for 
fine tuning and monitoring the whole process, as it progresses.
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EXHIBITS
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PTCA M A R K E T  A N A L Y S I S  /  T U R K E Y
P R O D U C T : A C S
CITY HOSPITAL #IN 94 f f ACS BY % #IN 95 # ACS BY % 96 ACS BY %
ANKARA TYIH
A.UNIVERSITY
GATA
ORGAN NAKLİ
HACETTEPE
GAZI UNIVERSITY
BAYINDIR
SSK
GÜVEN
YASAM
440 140 32% 458 103 22% 510 150 29%
410 120 29% 498 156 31% 550 135 25%
44 8 18% 50 16 32% 60 15 25%
70 9 13% 79 18 23% 90 0 0%
130 40 31% 166 42 25% 185 60 32%
64 14 22% 72 0 0% 80 15 19%
102 28 27% 105 23 22% 120 30 25%
135 35 26% 152 55 36% 170 25 1 5%
0 0 0 0 0 0
0 0 0 0 0 0
ISTANBUL KOSUYOLU 
GOGUS CERRAHİSİ 
HASEKI&FLO 
ÇAPA UNIVERSITY 
CERRAHPAŞA 
GATA
INTL HOSP.
408 112 27% 427 96 22% 480 140 29%
368 79 21% 413 109 26% 460 1 10 24%
480 96 20% 561 264 47% 600 130 22%
132 52 39% 188 21 11% 210 60 29%
35 5 14% 40 7 18% 50 10 20%
93 18 19% 106 5 5% 120 30 25%
83 18 22% 93 38 41% 100 25 25%
IZMIR EGE UNIV 
9 EYLÜL UNIV. 
DEVLET
550 102 19% 597 47 8% 700 80 1 1%
140 35 25% 151 51 34% 170 30 18%
0 0 0 0 0 0
ADANA ÇUKUROVA UNIV 
SEYHAN
108 25 23% 122 32 26% 140 50 36%
0 0 0 0 80 20 25%
KAYSERI ERCIYES UNIV 100 40 40% 128 37 29% 140 50 36%
ANTALYA AKDENİZ UNIV 58 10 17% 66 14 21% 70 20 29%
SAMSUN 19 MAYIS UNIV 40 14 35% 74 29 39% 80 20 25%
ESKİŞEHİR OSMANGAZI UN 146 12 8% 164 56 34% 180 60 33%
KONYA SELÇUK UNIV 13 4 31% 15 8 53% 15 5 33%
ERZURUM ATATÜRK UNIV 90 43 48% 97 42 43% 100 40 40%
TRABZON KARADENİZ T.UNIV 0 0 0 0 5 2 40%
T U R K E Y T O T A L 4239 1059 25% 4822 1269 26% 5465 n i 2 24%
PACEMAKER  M A R K E T  A N A L Y SIS  / T U R K E Y
P R O D U C T :  I N T E R M E D I C S
CITY HOSPITAL /^ IN 94 U INT. BY % U \ N  95 H INT. BY % 96 IN I. BY %
ANKARA TYIH
A.UNIVERSITY
GATA
ORGAN NAKLİ
HACETTEPE
GAZI UNIVERSITY
BAYINDIR
SSK
GÜVEN
YASAM
58 10 17% 60 7 12% 68 12 18%
68 5 7% 73 9 12% 69 35 51%
3 0 0% 4 0 0% 3 1 33%
10 0 0% 10 2 20% 14 2 14%
58 4 7% 60 8 13% 53 4 8%
5 1 20% 5 0 0% 5 1 20%
15 2 n% 16 2 13% 15 3 20%
24 5 21% 24' 4 17% 25 12%
0 0 0 0 0 0
0 0 0 0 0 0
ISTANBUL KOSUYOLU
GOGUS CERRAHİSİ
HASEKI*FLO
CARA UNIVERSITY
CERRAHPAŞA
GATA
INT’L HOSP.
68 9 13% 70 ]0 14% 65 16 25%
63 I 2% 71 5 7%. 58 10 17%
58 0 0% 63 10 16% 73 15 21%
39 10 26% 45 10 22% 41 18 44%
29 0 0% 29 3 10% 36 9 25%
19 0 0% 22 5 23% 20 4 20%
34 4 12% 31 5 16% 36 5 14%
IZMIR EGE UNIV 
9 EYLÜL UNIV. 
DEVLET
39 5 13% 32 9 28% 41 6 15%
29 4 14% 31 5 16%. 30 5 17%
49 5 10% 48 8 17%. 62 2.3 37%,
ADANA ÇUKUROVA UNIV 
SEYHAN
24 2 8% 22 5 23% 25 5 20%
15 2 13%. 18 4 22% L5 3 20%
KAYSERI ERCIYES UNIV 29 4 14% 29 6 21%. 32 9 28%
ANTALYA AKDENİZ UNIV 34 6 18% 34 5 15% 30 5 17%
SAMSUN 19 MAYIS UNIV 29 4 14% 29 6 21% 30 10 33%
ESKISEHIR OSMANGAZI UN 39 0 0% 40 4 10% 50 27 54%
KONYA SELÇUK UNIV 15 0 0% 15 3 20% 15 4 27%
ERZURUM ATATÜRK UNIV 24 8 33% 24 5 21% 25 4 U»%
TRABZON KARADENİZ T.UNIV 37 0 0% 38 5 13'M, 39 4 10%
T U R K E Y T O T A L 914 91 10% 943 145 1 5% 975 243 оси/ Z.» /0
H E A R T  V A L V E  M A R K E T  A N A L Y S I S  /  t U R K E ^
P R O D U C T : ATS
CITY HOSPITAL #IN 94 #  ATS BY % #IN 95 # ATS BY % 96 ATS BY %
ANKARA TYIH
A.UNIVERSITY
GATA
ORGAN nakli
HACETTEPE
GAZI UNIVERSITY
BAYINDIR
SSK
GÜVEN
YASAM
368 46 13% 347 31 9% 300 0 0%
. 127 0 0% 125 0 0% 100 0 0%
80 15 1 T/u 96 37 39% 90 50 56%
45 0 0% 42 0 0% 50 0 0%
265 0 0% 220 0 0% 200 0 0%
81 0 0% 72 0 0% 50 0 0%
46 8 17% 75 15 20% 100 0 0%
10 0 0% 24 , 0 0% 50 0 0%
0 0 122 14 11% 150 0 0%
0 0 0 0 50 40 80%
ISTANBUL KOSUYOLU
GOGUS CERRAHİSİ
HASEKI&FLO
ÇAPA UNIVERSITY
CERRAHPAŞA
GATA
INT'L HOSP.
214 36 17% 205 _______ü . 21% 200 40 20%
245 0 0% 189 0 0% 180 0 0%
170 19 11% 146 22 15% 120 0 {)%
47 0 0% 50 0 0% 70 0 0%
40 0 0% 37 0 0% 50 0 0%
17 0 0% 16 0 0% 30 0 0%
27 7 26% 28 0 0% 50 0 0%
IZMIR EGEUNIV 
9 EYLÜL UNIV. 
DEVLET
112 23 21% 115 0 0% 110 0 0%
20 0 0% 48 0 0% 60 0 0%
32 0 0 56 0 0% 70 0 0%
ADANA ÇUKUROVA UNIV 
SEYHAN
15 0 0% 30 0 0% 30 0 0%
0 0 0 0 40 0 0%
KAYSERİ ERCIYES UNIV 0 0 32 19 59% 50 40 80%
ANTALYA AKDENİZ UNIV 12 0 0% 25 0 0% 40 0 0%
SAMSUN 19 MAYIS UNIV 36 0 0% 40 0 0% 40 0 0%
ESKİŞEHİR OSMANGAZI UN 25 0 0% 29 0 0% 30 0 0%
KONYA SELÇUK UNIV 39 0 0% 39 0 0% 40 0 0%
ERZURUM ATATÜRK UNIV 55 15 27% 57 21 37% 60 0 0%
TRABZON KARADENİZ T.UNIV 0 0 0 0 10 0 0%
T U R K E Y T O T A L 2128 169 8% 2265 202 9% 2420 170 70 / / /0
O X Y G E N A T O R  M A R K E T  A N A L Y S I S  /  T U R K E Y
P R O D U C T : T E R U M O
I
CITY HOSPITAL #IN 94 # BY % #1N 95 # BY % 96 BY %
TERUMO TERUMO TERUMO
ANKARA TYIH 1482 893 60% 1515 1264 83% 1500 500 33%
A.UNIVERSITY 318 0 0% 330 0 0% 320 0 0%
GATA 601 341 57% 634 453 71% 650 0 0%
ORGAN NAKLİ 362 0 0% 381 0 0% 370 0 0%
HACETTEPE 977 0 0% 920 0 0% 950 0 0%
GAZI UNIVERSITY 214 95 44% 211 175 83% 250 0 0%
BAYINDIR 463 300 65% 593 314 53% 600 100 17%
SSK 46 0% 124 0 0% 100 0 0%
GÜVEN 0 469 345 74% 800 300 38%
YASAM 0 0 0 200 200 100%
ISTANBUL KOSUYOLU 953 453 48% 920 352 38% 900 0 0%
GOGUS CERRAHİSİ 1245 0 0% 1182 .54 5% 1200 0 0%
HASEKIAFLO 9.S6 386 40% 860 37 4% 900 200 22%
ÇAPA UNIVERSITY 325 0 0% 286 0 0% 300 0 ()'>u
CERRAHPAŞA 99 0 0% 120 0 0% 150 0 n%
GATA 126 0 0% 158 0 0% 130 0 oy.,
INTL HOSP.. 312 0 0% 425 0 0% 450 0 0%
IZMIR EGE UNIV 658 423 64% 624 368 59% 600 0 0%
9 EYLÜL UNIV. 161 0 0% 185 69 37% 200 0 0%
DEVLET 234 0 0 199 0 0% 200 0 0%
ADANA ÇUKUROVA UNIV 79 0 0% 96 0 0% 100 0 0%
SEYHAN 0 0 0 0 100 0 n%
KAYSERI r.RCIYES UNIV 0 0 81 70 86% 150 100 (.7%
ANTALYA AKDENİZ UNIV 51 27 53% 86 0 0% 100 0 iWu
SAMSUN 19 MAYIS UNIV 97 12 12% 116 0 0% 120 0 0%
ESKISEIIIR OSMANGAZI UN 88 0 0% 91 12 13% loo 0 0%
KONYA SELÇUK UNIV 69 0 0% 89 0 0% 100 0 0%
ERZURUM ATATÜRK UNIV 92 37 40% 100 42 42% 100 0 0%
TRABZON KARADENİZ T.UNIV 0 0 0 0 20 0 0%
T U R K E Y T O T A L 10008 2967 30% 10795 3555 33% 11660 1400 12%
1994
TOTAL SALES: 
Gross Profit Marjiin
PRODUCT
MARKET
SIZE
S 7,()0(),(MI(I 
30%
UNIT
SALES
MARKET PERCENT OF PERCENT OF 
SHARE SALES G.PROFIT
Oxygenator 10.008 pcs. 2.967 pcs. 30% 17% r %
Pacemaker 914 pcs. 91 pcs. 10% 16% 25%
PTCA 4.239 pcs. 1.059 pcs. 25% 20% 24%
Heart Valves 2.128 pcs. 169 pcs. 8% 7% 5'’o
1995
TOTAL SALES ; 
Gross Profit Margin :
S 7,150,00(1 
27%
PRODUCT
MARKET
SIZE
UNIT
SALES
MARKET
SHARE
PERCENT OF PERCENT OF 
SALES G.PROnT
Oxvoenator 10.795 pcs. 3.555 pcs. 33% 18% 13%
Pacemaker 943 pcs. 145 pcs. 15% 22% .>4%
PTCA 4.822 pcs. 1.269 pcs. 26% 22% 26”o
Heart Valves 2.265 pcs. 202 pcs. 9% 8% 5"'o
1996
SALES
Gross Profit Margin ;
S 6,100,000 
33%
PRODUCT
MARKET
SIZE
UNIT
SALES
MARKET
SHARE
PERCENT OF PERCENT OF 
SALES G.PROFIT
Oxy<;enator 11.660 pcs. 1,400 pcs. 12% 8% 5“i.
Pacemaker 975 pcs. 243 pcs. 25% 43% 52%
PTCA 5.465 pcs. 1.312 pcs. 24% 26% 25%
Heart Valves 2,420 pcs. 170 pcs. 7% 8% 4%
EXHIBIT - 5 -
HOSPITALS IN TURKEY
Year Number o f Hosp, Patient Bed Num Population/bed
1923 86 6.437 1.920
1925 167 9.561 1.360
1930 182 11.398 1.260
1935 176 13.038 1.240
1940 198 14.383 1.240
1945 197 16.133 1.160
1950 301 18.837 1.100
1955 '  · 426 34.526 690
1960 566 45.807 600
1965 626 55.451 560
1970 746 71.876 490
1975 798 81.264 493
1985 827 99.117 451
1990 722 103.918 495
1991 736 107.152 481
1992 756 111.135 475
1993 777 113.010 479
1994 812 116.061 479
Population/bed
■ PoDulation/bed
EXHIBIT - 6 -
HOSPITAL BREAKDOWN BY THE HEALTH CARE AGENCY
NAME OF THE INSTITUTION NUMBER OF PATIENT BEDS
HOSPITALS NUMBER PERCENTAGE
MINISTRY OF HEALTH 549 68.258 51,7
MINISTRY OF DEFENCE 42 15.900 12,0
SOCIAL SECURITY AGENCY (SSK) 91 20.129 15,2
PUBLIC ECONOMICAL ORGANISATIONS 15 2.146 1,6
OTHER MINISTRIES 3 780 0,6
MEDICAL FACULTIES 24 17.749 13,4
MUNICIPALITIES 5 1.160 0,9
PUBLIC ASSOCIATIONS 10 621 0,5
FOREIGNERS 8 670 0,5
MINORITIES 5 934 0,7
PRIVATE 102 3.614 2,7
TO TA L 854 131.961 100,0
MEDICAL
FACULTIES
14%
SOCIAL 
SECURITY 
AGENCY (SSK) 
16%
PRIVATE 
3%
PUBLIC
ECONOMICAL
ORGANISATIONS
2%
MINISTRY OF 
DEFENCE 
12%
MINISTRY OF 
HEALTH 
53%
EXHIBIT - 7 -
p a tie n ts  by  h e a l t h  c ar e  c o v e r a g e
INSTITUTION PERCENTAGE
STATE ORGANISATION 16
SOCIAL SECURITY AGENCY (SSK) 46
EMPLOYER'S HEALTH FUND 11
PENSION FUND 19
NOT COVERED 8
PERCENTAGE
PENSION
FUND
19%
NOT
COVERED
8%
STATE
ORGANIS.
16%
e m p l o y e r s
HEALTH FUND 
11%
SOCIAL
SECURITY
AGENCY
(SSK)
46%
EXHIBIT - 8 -
CHANGE IN DOLLAR EXCHANGE RATES
YEAR PERCENTAGE
CHANGE
1981 28
1982 43
1983 32
1984 46
1985 43
1986 27
1987 30
1988 35
1989 62
1990 23
1991 24
1992 29
1993 80
1994 60
1995 95
1996 135
PERCENTAGE
CHANGE
-PERCENTAGE
1980 1985 1990 1995 2000
EXHIBIT - 9 -
Z “Л Г“ > H О Z Z H c 7) 7: m -<
INFLATION FIGURES
YEAR WHOLE SALER 
PRICE
CONSUMER
PRICE
1970 8 1 8,13
1971 16.45 16,5
1972 16.75 13,68
1973 20,75 15,96
1974 28,4 18,63
1975 10:75 19,77
1976
>
16.45 16,39
1977 26,3 27,95
1978 53,1 47,21
1979 69,5 56,81
1980 98.75 115,6
1981 35,45 33,91
1982 26,53 21,91
1983 29,73 31,39
1984 49,53 48,4
1985 41,63 44,95
1986 27.93 34,62
1987 36,77 38,85
1988 64,55 73,7
1989 67,3 63,27
1990 52,25 60,3
1991 54 66
1992 61,4 70,1
1993 60,3 66,1
1994 149,6 125,5
1995 64,9 78,9
EXHIBIT - 11 -
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The research and analysis for the above thesis was completed September 1996 and 
presented to Biotek Medikal for their strategic consideration.
EPILOGUE:
Biotek Medikal tried to implement the last strategy suggested in the thesis (see pp, 45). In 
the CRD field the sub-dealer sister companies have been established, and in the CVS field 
Biotek was managing itself with its core office staff However, the bank loans and 
accompnying interest payment became a threatening burden on Biotek Medikal after the 
national economic crisis of 1994. The bank recalled its loans and interest payments putting 
Biotek in a financially precarious position.
The strategy outlined in the thesis seemed to be working well, until Biotek fell into deeper 
financial difficulties while trying to cope with the payment o f the loans and interests.
Biotek was trying desperately to obtain additional credit from other, more understanding, 
banks.
The profit margin, which had proven to be quiet reasonable for the organization, was not 
sufficient to save Biotek in its particular, negative financial situation. Then when the 
manufacturing companies recognized Biotek's dire financial situation they started to switch 
to "credit hold" position, which meant they stopped any further shipments until a certain 
amount o f money had been transferred.
These conditions were compounded when the income tax oblibations which followed the 
1994 crisis finally hit Biotek. The combined result was to totally weaken Biotek's overall 
credibility in front o f the government, banks and the related foreign companies.
The sister companies began to contact foreign companies themselves in order to survive in 
the field. They even became competitor to Biotek trying to get in touch with Biotek's own 
suppliers.
Soon Biotek had to announce a fake bankruptcy declaring that there was not enough 
resources to payoff their debts to government, foreign companies and even to their 
employees.
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THE COMPETITORS THROUGH 1998:
Medistar has improved its out-of-lstanbul sales force (see strength & weakness analysis 
pp. 30) and invested well to utilize Biotek's struggle as an opportunity for itself It may be 
considered to be more powerful than in 1996.
ETA once also thought o f a fake bankruptcy because o f nearly the identical reasons o f 
Biotek, but then the shareholders decided to invest money in the business to survive.
Because o f the same reasons ETA also has lost reliability and trust in the market.
Although being the first in the medical disposable market and once having a big sales 
potential, now ETA is not considered as a big competitor.
Bicakcilar is well implemented the cost leadership o f the Porter's generic strategies (thesis 
pp.29) and still runs in the separate avenue manufacturing its products and having a big 
price advantage over the competitors. Now, it is one o f the biggest companies in the 
medical market.
Sister companies have found their own foreign supplier companies and have achieved 
their places in the market using their good reputations that came fi"om the strong days of 
Biotek. As the market conditions and profit margins changed significantly in this sector, 
they are now trying to implement "focused differentiation" o f Porter's generic strategies 
along with trying to minimize the total company expenses.
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